Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

As uncertain tariff news continues to dominate Wall Street, Indiana's economy may be impacted. Jane King, a Nasdaq Analyst, ...

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company ...

Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

TOKYO-Nintendo's new Switch 2 videogame machine uses a rare-earth magnet to attach its hand-held controllers to the main console, according to a teardown, highlighting the company's vulnerability to ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

S&P 500, Microsoft Corporation, JPMorgan Chase & Co, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...